---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056934"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:20:57.426054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma reports Q1 net loss $10.3M; neffy PDUFA date Oct 2, 2024; cash $223.6M

## Summary
- Cash and securities $223.6M as of March 31, 2024; expected operating runway at least three years.
- Net loss $10.3M for Q1 2024 compared to $15.0M in Q1 2023; R&D expenses $5.2M, G&A $8.0M.
- FDA PDUFA target date for neffy NDA is October 2, 2024; CRL response submitted April 2.
- European CHMP opinion on neffy MAA expected in Q2 2024; Day 180 response submitted April 30.
- Exclusive license agreement with CSL Seqirus for Australia and New Zealand; up to $5M in payments.

## SEC filing metadata
- accession: 0000950170-24-056934
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/0000950170-24-056934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/spry-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056934
- JSON: https://secwatch.observer/filing/0000950170-24-056934.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056934.txt

## Key facts
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/0000950170-24-056934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.